BioMelbourne Network

📰 Member news    4DMedical wins contract to supply lung imaging technology to US radiology company. The Peter Doherty Institute for Infection and Immunity and the University of Calgary partner to award $175,000 in grant funding. Starpharma receives positive feedback from FDA on the DEP SN38 clinical pathway for platinum-resistant ovarian cancer. Cartherics Pty Ltd has been awarded a US$300K G-Rex grant to support clinical manufacturing of its lead product CTH-401 for upcoming clinical trials. Amplia Therapeutics Limited reports positive new data and strong recruitment in pancreatic cancer trial.   Immutep Limited reports promising new data in head and neck cancer at ESMO Immuno-Oncology 2024.   INOVIQ Ltd (ASX:IIQ) successfully completed stage 1 of its development program for an exosome therapeutic for breast cancer.     Monash Children’s Hospital scientists have successfully collected and reinfused umbilical cord blood cells in extremely premature babies, offering a glimmer of hope for preventing brain injuries.   ➡️ https://lnkd.in/gE-aB9tU

Australia’s Cell and Gene Catalyst has called for EOIs to serve on the 2025 Expert Working Groups. Representing the broader ecosystem, the working groups contribute to Australia’s rapidly growing cell and gene industry in four priority areas: • Policy & Advocacy • Manufacturing (new in 2025) • Collaboration & Knowledge-Sharing • Workforce Development Apply now and play a key role in shaping Australia’s future in cell and gene therapy. ➡️ https://lnkd.in/g4_AnA_y

Ashen is seeking recommendations for manufacturers to produce a microfluidics device, with a preference for Australian-based companies but is open to overseas options. If you know of any manufacturers or have valuable recommendations, let Ashen know. ➡️ https://lnkd.in/gqritkem

New member Mérieux NutriSciences is a global leader in providing scientific services focused on enhancing food safety, quality assurance, and public health. In addition to our expertise in food testing, we are a trusted partner to the pharmaceutical industry, offering a comprehensive range of research, development, and analytical services to ensure the safety and quality of biopharma products. Our services support Australian pharmaceutical manufacturers in meeting rigorous regulatory standards and ensuring the microbiological quality of their products. Our fully equipped, state-of-the-art laboratories offer a range of pharmaceutical testing services, including excipient testing, active pharmaceutical ingredients (APIs), and finished pharmaceutical products. ➡️ https://lnkd.in/gN8k_FJy

BioMelbourne Network is developing its new three-year strategic plan, and is seeking expressions of interest from individuals and organisations who can help shape this important process. The strategic plan will set the direction for BioMelbourne Network growth and impact over the next three years. It will provide a roadmap for achieving our mission, enhancing our network, and increasing impact when serving the needs of our ecosystem. We look forward to shaping the future of BioMelbourne Network together. ➡️ https://lnkd.in/gQSvzfbP

Further bolstering Australia’s vision to see more local SME health technology procured domestically, Pathology Technology Australia, the Association of Healthcare Supply and Procurement Officers and the Medical Technology Association of Australia (MTAA) have joined the Australian Medtech Manufacturing Alliance steering group.    Led by BioMelbourne Network, this new and collaborative initiative brings together leading expertise from peak industry bodies and companies to create a unified industry voice, and advocate on behalf of Victorian SME medtech manufacturers across the key issues impacting the sector.    The Alliance has been seed-funded by the @State Government of Victoria Department of Jobs, Skills, Industry and Regions; the pilot programme aims to support and empower the national agenda.    Karen Parr, CEO of BioMelbourne Network and Alliance lead, noted, “With industry and health two sides to the same coin, it’s critical to the Alliance’s success to have both perspectives in the room to drive meaningful outcomes.”    The partnership focuses on addressing critical challenges and creating new opportunities for Australian medtech manufacturers.    The Alliance invites established Victorian medtech companies that are currently manufacturing medtech products and selling locally or globally, and contract manufacturing and development companies to participate. ➡️ https://lnkd.in/gNVgRCBV #AMMA

🆕 New member Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer. Our world class team of cell therapy pioneers is focused on the discovery, development, and commercialisation of todays most innovative solutions, and has shown a consistent ability to deliver on its objectives. Chimeric's diversified portfolio includes first in class autologous CAR T cell therapies and best in class allogeneic NK cell therapies, with assets being developed across multiple different disease areas in oncology with 3 clinical stage programs. ➡️ https://lnkd.in/gZrMtnQU

CCRM Australia is offering an opportunity for two Australian trainees to attend Summer by Design in 2025, focusing on skill development in the clinical translation and commercialisation of regenerative medicine-related therapies. Applications close on 20 December 2024; to apply, please contact Dr. Chih Wei Teng at [email protected]. ➡️ https://lnkd.in/gVzHKVMi

With a specific focus on the pre-seed stage of research innovation, the ‘Commercialisation Training for Medical and Med Tech Researchers’ training program will equip early and mid-career researchers with fundamental knowledge in research commercialisation and the opportunity to partner with industry to progress their ground-breaking research ideas. If you are a researcher in a Victorian MRI register your interest now. ➡️ https://lnkd.in/g88QAkZ7

As the year comes to a close, we’d like to share that the BioMelbourne Network office is closing from COB Friday 20 December, and reopening on Monday 6 January 2025. Looking ahead to 2025, we’re thrilled to offer you new programs and opportunities, including an exciting calendar of events aimed at fostering collaboration and growth across our sector. Be sure to subscribe to In the Loop to stay updated on all our plans, sector news and our advocacy. ➡️ https://lnkd.in/gCnHu-f The newsletter will return on Thursday 16 January 2025, and ready to hit the ground running. BioMelbourne Network wishes you all a happy and safe holiday season. We look forward to reconnecting as we embark on another successful year.